Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) had its target price lowered by Morgan Stanley from $104.00 to $75.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Morgan Stanley‘s price target would indicate a potential upside of 158.44% from the stock’s previous close.
IONS has been the topic of several other research reports. BMO Capital Markets raised shares of Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $54.00 to $66.00 in a research report on Thursday, October 22nd. Canaccord Genuity Group lowered their price objective on Ionis Pharmaceuticals from $95.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, September 8th. Guggenheim cut their target price on Ionis Pharmaceuticals from $89.00 to $80.00 and set a “buy” rating for the company in a research note on Tuesday, September 15th. HC Wainwright reduced their target price on Ionis Pharmaceuticals from $100.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Wolfe Research lowered Ionis Pharmaceuticals from an “outperform” rating to a “peer perform” rating in a research note on Thursday, July 16th. Nineteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $78.71.
View Our Latest Stock Analysis on Ionis Pharmaceuticals
Ionis Pharmaceuticals Trading Down 6.4%
Shares of NASDAQ IONS traded down $1.98 during trading on Tuesday, hitting $29.02. 2,293,831 shares of the company were exchanged, compared to its average volume of 2,744,755. Ionis Pharmaceuticals has a 12-month low of $27.75 and a 12-month high of $86.74. The company has a debt-to-equity ratio of 3.07, a quick ratio of 7.73 and a current ratio of 7.89. The company has a fifty day moving average price of $46.20 and a 200-day moving average price of $65.63. The firm has a market capitalization of $4.82 billion, a PE ratio of -8.39 and a beta of 0.43.
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($1.23) by $0.57. The company had revenue of $242.72 million for the quarter, compared to analyst estimates of $178.17 million. Ionis Pharmaceuticals had a negative net margin of 64.76% and a negative return on equity of 111.08%. Ionis Pharmaceuticals’s revenue was up 54.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.80) EPS. As a group, equities research analysts expect that Ionis Pharmaceuticals will post -3.62 EPS for the current year.
Insider Activity at Ionis Pharmaceuticals
In other news, EVP Shannon Devers sold 1,357 shares of the company’s stock in a transaction dated Friday, October 16th. The stock was sold at an average price of $43.54, for a total transaction of $59,083.78. Following the completion of the transaction, the executive vice president directly owned 17,811 shares of the company’s stock, valued at approximately $775,490.94. This represents a 7.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 1.81% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the company. Alyeska Investment Group L.P. increased its holdings in shares of Ionis Pharmaceuticals by 199.7% in the 2nd quarter. Alyeska Investment Group L.P. now owns 1,417,916 shares of the company’s stock valued at $112,427,000 after purchasing an additional 944,766 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of Ionis Pharmaceuticals during the 2nd quarter valued at approximately $62,718,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Ionis Pharmaceuticals during the 2nd quarter valued at approximately $54,253,000. TimesSquare Capital Management LLC purchased a new stake in shares of Ionis Pharmaceuticals during the 2nd quarter worth approximately $48,690,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Ionis Pharmaceuticals during the 2nd quarter worth approximately $43,011,000. Institutional investors and hedge funds own 93.86% of the company’s stock.
Key Ionis Pharmaceuticals News
Here are the key news stories impacting Ionis Pharmaceuticals this week:
- Positive Sentiment: Ionis reported third-quarter revenue of about $243 million, up roughly 55% year over year and above expectations. Its quarterly loss was also narrower than analysts had forecast. Read More.
- Positive Sentiment: DAWNZERA sales grew 40% to $37 million, providing a positive commercial update amid weakness in TRYNGOLZA’s launch. Read More.
- Negative Sentiment: Ionis cut its 2026 TRYNGOLZA sales outlook to approximately $50 million, down from its prior $100 million–$110 million target. The company cited slower-than-expected uptake and competitive pressure, undermining expectations for the drug’s commercial potential. Read More.
- Negative Sentiment: Ionis guided to 2026 revenue of $875 million–$900 million, below the roughly $921 million consensus estimate, adding to concerns about near-term growth. Read More.
- Negative Sentiment: Law firms announced investigations into potential investor claims related to Ionis, adding a legal overhang following the sales forecast reduction. These announcements concern potential claims and do not establish wrongdoing. Read More.
- Negative Sentiment: HC Wainwright and Needham lowered their price targets to $70 and $54, respectively, although both maintained Buy ratings. Read More. · Read More.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases.
Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.
Featured Stories
- Five stocks we like better than Ionis Pharmaceuticals
- DraftKings Just Lost 20%—And Its Biggest Gamble Is Still Ahead
- Barrick’s Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity
- Axon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?
- Wall Street May Be Making a Big Mistake With monday.com Stock
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
